There are 3161 resources available
1810P - MYC expression defines distinct transcriptomic landscape and affects response to DNA-damaging therapies in SCLC
Presenter: Caterina de Rosa
Session: Poster session 07
1812TiP - IDeate-Lung03: A Phase Ib/II study of ifinatamab deruxtecan (I-DXd) plus atezolizumab (atezo) with or without carboplatin (carbo) as first-line (1L) induction or maintenance in patients (pts) with extensive stage (ES) small cell lung cancer (SCLC)
Presenter: Charles Rudin
Session: Poster session 07
1813TiP - Debio 0123, a highly selective WEE1 inhibitor, combined with carboplatin (CP) and etoposide (ETOP) in patients (pts) with small cell lung cancer (SCLC) that progressed after platinum-based therapy: A phase I dose escalation and expansion study
Presenter: Valentina Gambardella
Session: Poster session 07
2P - Single-cell profiling and integrative TCR analysis reveals tumor-mutation associated phenotypes and immune repertoire in lung adenocarcinoma
Presenter: Alexander Lozano
Session: Poster session 07
3P - Metabolic reprogramming induced by KEAP1 mutation in NSCLC
Presenter: Renata Akhmetzianova
Session: Poster session 07
4P - CBL-B inhibition overcomes PD-1/LAG-3 mediated resistance in lung cancer
Presenter: Luisa Chocarro
Session: Poster session 07
5P - Circulating tumor cell-derived organoids from lung adenocarcinoma patients for assessment of EGFR and KRAS mutations
Presenter: Mohamed Lahmadi
Session: Poster session 07
6P - Circulating low-density neutrophils (LDNs) are associated with resistance to immunotherapy as frontline treatment for non-small cell lung cancer (NSCLC): Updated results and proteomic characterization
Presenter: Natalia Castro Unanua
Session: Poster session 07
7P - Association study between genetic variants in regulatory gene for RNA modification and prognosis in non-small cell lung cancer
Presenter: Eungbae Lee
Session: Poster session 07